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For the vast majority of patients, a di-
agnosis of cancer triggers fundamentally
the same course of therapy as it has for the
past 40 to 50 years: surgery (when possi-
ble), followed by treatment with noxious
chemotherapeutic agents. Certainly, there
has been steady improvement in the effec-
tiveness of these therapies and accordingly
in the prognoses associated with many can-
cers. Yet all too often cancer remains a
death sentence, forewarning patients to
brace for a course of therapy that can be
both profoundly difficult and profoundly
ineffective in the long term.
The dire situation in the clinic contrasts
starkly with the spectacular advances made
in the laboratory over the same 50-year pe-
riod.Geneticists,cellbiologists,biochemists,
immunologists, and molecular biologists
haveprovidedatreasuretroveofinformation
concerning the origins of cancer, the signal-
ingpathwaysresponsibleforthegrowthand
maintenance of cancer cells, and the body’s
response (and lack of response) to tumors.
But most of these conceptual insights have
not provided the type of breakthroughs in
cancercarethatscientistsandsocietyatlarge
so deeply crave. Why?
The reasons are complex, with the first
being that cancer itself is complex. It is not
asingle disorder; and even within aspecific
typeorsubtypeofcancer,thereisincredible
individual and even cell-to-cell variation.
Cancer cells are capable of microevolution
on a rapid scale, with adaptation to
chemotherapeuticsbeingdrivenbybothge-
netic and epigenetic mechanisms.
Second, except in those relatively rare
cases in which a cancer is driven by a spe-
cific mutation, multiple changes in gene ex-
pression and cell biology conspire to
endow tumors to live as a coherent commu-
nity of unwanted residents within the larger
community of normal tissues and organs.
As a result, it is extremely unlikely that any
single drug or drug target ever will be a
fully effective approach to therapy.
Third (and this is by no means a com-
plete list), but arguably most important, it is
exceedingly difficult to study cancer in the
only organism that really matters: the
human cancer patient. The extraordinary
insights we have achieved come predomi-
nantly from the study of worms, flies, and
mice. The identification of mutations and
other genetic abnormalities leading to can-
cer has, of course, been accomplished by
brilliant studies of human populations, but
these have provided information that is
largely descriptive and correlative: It is dif-
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ficult to test the hypotheses and complex
predictions set up by these observations.
I mention all this not for the sake of in-
stilling a sense of despair — far from it. In
fact, we find ourselves at a time of excep-
tional change in our understanding of cancer
in humans. Biotech and biopharma compa-
nies now are beginning to generate a com-
pletely new set of agents that fall into the
broad category of “targeted therapies,” the
existence of which is owed to decades of
work understanding cancer mechanisms.
While conventional chemotherapeutics rep-
resent broad spectrum anti-mitotics or cyto-
toxics (which kill normal cells almost as
effectively as cancer cells), targeted thera-
pies address features far more selective to
cancer cells. Sometimes, these can be mu-
tant or normal gene products made only in
certain cancers, but more frequently, they
are proteins or pathways on which cancer
cells rely far more heavily than normal cells.
Several of these are already in the clinic,
some already approved for use. Their effec-
tiveness may appear modest at times, but in
general, targeted therapies seem to have a far
higher therapeutic index, i.e., they exert their
benefit without as many off-target side ef-
fects.
The advent of targeted agents is not the
end of the story, however. Monotherapy
seems less and less likely to comprise an ef-
fective approach to cancer. As a result, we
need to understand how the new targeted
agents should be combined and adminis-
tered,whichbringsusbacktotheprimacyof
the research enterprise. We need to devote
time, attention, resources, and rewards to the
study of human cancer in human patients.
What happens at the cellular level when we
inhibit PI-3-kinase in conjunction with
blocking angiogenesis in ovarian cancer?
Might it have been better to inhibit Akt in
conjunction with PARP? Or to deliver a po-
tentcytotoxicdrugconjugatedtoanantibody
vehicle that selectively targets the cancer
cells? Such questions are easy to pose but
difficulttoanswer.Assayslike“progression-
free survival” or “tumor shrinkage” are
crude, slow, and not very helpful for eluci-
dating the mechanisms underlying a given
treatment regimen. What we need are bio-
chemicalandfunctionaltoolstoassaytheef-
fects of our attempts to treat patients, in real
time and with minimally invasive methods.
Such data will greatly enhance our efforts to
understand the fundamental cell biology and
development of cancer in the only organism
where it really matters. It is from this infor-
mation that, in my view, the true break-
throughs in cancer therapy will emerge.
This is our challenge. It is a grand and
an exciting one, not only scientifically but
also because of the extraordinary benefit to
society that will come from our eventual
success.